DGX Earnings & Financial Statements
Quest Diagnostics Incorporated
$233.43
+$2.97(+1.29%)
65
Overall
100
Value
36
Tech
60
Quality
Market Cap
$25.76B
Volume
1.20M
52W Range
$171.18 - $248.84
Target Price
$252.19
DGX earnings and financial statements: Quest Diagnostics Incorporated's income statement, balance sheet and cash flow statement, annual and quarterly.
DGX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Cost of revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B |
| EBITDA | $2.19B | $1.89B | $1.75B | $1.86B | $3.16B |
| Net income | $992.00M | $871.00M | $854.00M | $946.00M | $2.00B |
| EPS (diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B |
| Total liabilities | $8.94B | $9.26B | $7.60B | $6.83B | $7.13B |
| Shareholders’ equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B |
| Cash and equivalents | $420.00M | $549.00M | $686.00M | $315.00M | $872.00M |
| Long-term debt | $5.70B | $6.15B | $4.91B | $4.47B | $4.50B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B |
| Capital expenditure | -$527.00M | -$425.00M | -$408.00M | -$404.00M | -$403.00M |
| Free cash flow | $1.36B | $909.00M | $864.00M | $1.31B | $1.83B |
| Dividends paid | $409.00M | $378.00M | $371.00M | $378.00M | $408.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DGX | $233.43 | +1.3% | 1.20M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Quest Diagnostics Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW